Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Posted by on Jul 2nd, 2026

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the six analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $30.00.

Several research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of Kyverna Therapeutics in a research note on Wednesday, June 3rd. Wall Street Zen cut shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. JPMorgan Chase & Co. dropped their target price on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Wednesday, June 24th.

Read Our Latest Analysis on KYTX

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. AIGH Capital Management LLC raised its position in Kyverna Therapeutics by 33.3% during the 1st quarter. AIGH Capital Management LLC now owns 2,000,000 shares of the company’s stock valued at $17,260,000 after purchasing an additional 500,000 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Kyverna Therapeutics by 16.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,762,617 shares of the company’s stock worth $16,569,000 after buying an additional 250,418 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in shares of Kyverna Therapeutics during the fourth quarter valued at $15,667,000. Vanguard Group Inc. increased its stake in shares of Kyverna Therapeutics by 0.8% during the third quarter. Vanguard Group Inc. now owns 1,322,625 shares of the company’s stock valued at $7,936,000 after buying an additional 9,858 shares during the period. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Kyverna Therapeutics in the fourth quarter valued at about $9,220,000. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

Kyverna Therapeutics Stock Performance

Shares of Kyverna Therapeutics stock opened at $8.44 on Thursday. The stock’s fifty day moving average is $8.70 and its two-hundred day moving average is $8.62. The company has a market capitalization of $513.07 million, a PE ratio of -2.57 and a beta of 1.87. The company has a quick ratio of 8.15, a current ratio of 8.15 and a debt-to-equity ratio of 0.13. Kyverna Therapeutics has a 52 week low of $2.52 and a 52 week high of $13.67.

Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09. As a group, analysts expect that Kyverna Therapeutics will post -2.78 earnings per share for the current year.

Kyverna Therapeutics Company Profile

(Get Free Report)

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.

Featured Articles

Analyst Recommendations for Kyverna Therapeutics (NASDAQ:KYTX)

Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.